about
Pharmacotherapy for Status EpilepticusPropofol protects against focal cerebral ischemia via inhibition of microglia-mediated proinflammatory cytokines in a rat model of experimental strokeImmunosuppressive aspects of analgesics and sedatives used in mechanically ventilated patients: an underappreciated risk factor for the development of ventilator-associated pneumonia in critically ill patients.Anesthetic propofol reduces endotoxic inflammation by inhibiting reactive oxygen species-regulated Akt/IKKβ/NF-κB signaling.Propofol Treatment Inhibits Constitutive Apoptosis in Human Primary Neutrophils and Granulocyte-Differentiated Human HL60 Cells.Effect of propofol and sevoflurane on the inflammatory response of patients undergoing craniotomy.Propofol attenuates hydrogenperoxide-induced apoptosis in human umbilical vein endothelial cells via multiple signaling pathwaysBarriers to glucose control in the intensive care unit.Economic evaluation of sustained sedation/analgesia in the intensive care unit.Late pharmacologic conditioning with volatile anesthetics after cardiac surgery.Choice of anesthetic technique on plasma concentrations of interleukins and cell adhesion molecules.Propofol Attenuates Toxic Oxidative Stress by CCl4 in Liver Mitochondria and Blood in Rat.Inhibitory effects of propofol on Th17 cell differentiation.Propofol Sedation Exacerbates Kidney Pathology and Dissemination of Bacteria during Staphylococcus aureus Bloodstream Infections.Propofol inhibits expression of angiotensin II receptor type 2 in dorsal root ganglion neurons.Role of HMGB1 in propofol protection of rat intestinal epithelial cells injured by heat shock.Activation of PI3K-Akt through taurine is critical for propofol to protect rat cardiomyocytes from doxorubicin-induced toxicity.The modulating effects of propofol and its lipid carrier on canine neutrophil functionsTourniquet-induced ischemia-reperfusion injuries during extremity surgery at children's age: impact of anesthetic chemical structure.Propofol exerts anti-inflammatory effects in rats with lipopolysaccharide-induced acute lung injury by inhibition of CD14 and TLR4 expressionProbe substrate and enzyme source-dependent inhibition of UDP-glucuronosyltransferase (UGT) 1A9 by wogonin.Attenuation of cisplathin-induced toxic oxidative stress by propofol.Propofol suppresses prostaglandin E(2) production in human peripheral monocytes.Propofol sedation in total knee replacement : effects on oxidative stress and ischemia-reperfusion damage.Propofol increases angiotensin-converting enzyme 2 expression in human pulmonary artery endothelial cells.Propofol Attenuates Inflammatory Response in LPS-Activated Microglia by Regulating the miR-155/SOCS1 Pathway.Lactate-to-pyruvate ratio as a marker of propofol infusion syndrome after subarachnoid hemorrhage.Comparison of the expression of cluster of differentiation (CD)39 and CD73 between propofol- and sevoflurane-based anaesthesia during open heart surgery.Endothelial-cell inflammation and damage by reactive oxygen species are prevented by propofol via ABCA1-mediated cholesterol efflux.
P2860
Q26796689-92A69139-A174-4136-9262-EBFBEB1D75C3Q28392617-A160400E-3BD5-4698-80A8-04E65054B2EFQ33737145-DDC8B252-916C-4356-8C9F-C5D86BB3BC38Q33847440-67360581-8999-4D13-B285-323886582839Q35659881-E523CC55-0214-4A4A-A20C-009C76926B56Q35965492-D0BD6EAD-1FE1-48BE-B583-C28028FFD6D1Q36177203-0B51E6EB-0DA3-4464-A9FD-02F1D48F10C4Q36390908-106C7232-FD12-407C-B9FC-D128C57728BEQ36613928-395C0DA7-F210-426F-9557-97D893C74BF6Q36928217-429116DE-5171-4F45-A960-F706DED70E5AQ37660558-EEA8D587-4782-4B0A-99AB-3C5BA09AADC6Q37700676-0247E8B5-EBBA-4E5F-A241-78813A986FE5Q38757761-9CDFAA80-CAB0-433A-9F54-0F9298BB34F1Q38810248-C113ED4B-CE6D-442C-B287-F4647CB14DDEQ39156357-DB738E19-6FC5-483D-BDE8-59363CF2D6A0Q39201813-947194A1-E682-465F-BB45-FC0BDA0B16E8Q39212248-FD0F8A70-E7FC-4048-B227-CC4949A6DAE1Q42330112-90767F3E-FA6B-4BDB-93E5-94F487F7F6A0Q42686652-89CD3523-F756-4D86-828C-BD549A5F9D9FQ42839015-86CD8043-BCA8-4E02-AA98-6115824A48B5Q42912104-A38DCFAB-E37D-41A5-BA67-2E9F0B8CBF82Q43095434-D1742126-DB1F-4B82-9C22-029C17C001BFQ43232967-0E2B9783-7F8D-46E6-B22A-600D9A77A278Q47994725-A1876CD9-EA48-4EAB-AC44-C2121F5195EFQ48120793-4B30D4C8-2B45-4F9F-BD97-035F3171444AQ48125853-D2DBEEFE-20B0-4188-B764-2CB26742451FQ48313012-C4529519-A319-4287-9E09-A7209AB6CDC7Q55618915-4823E26D-D70D-4AD8-A831-D177DC8B999EQ55692415-100A50DD-57BF-4A49-8F59-71BDB7487599
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Propofol: an immunomodulating agent.
@ast
Propofol: an immunomodulating agent.
@en
type
label
Propofol: an immunomodulating agent.
@ast
Propofol: an immunomodulating agent.
@en
prefLabel
Propofol: an immunomodulating agent.
@ast
Propofol: an immunomodulating agent.
@en
P2860
P1433
P1476
Propofol: an immunomodulating agent.
@en
P2093
Paul E Marik
P2860
P304
P356
10.1592/PHCO.2005.25.5_PART_2.28S
P407
P433
P577
2005-05-01T00:00:00Z